

JC14 Rec'd PCT/PTO 25 APR 2002

SLR:dm 4/25/02 113163.doc 4239-58051

PATENT

TECH CENTER 1600/2900

MAY 14 2002

RECEIVED

KLARQUIST SPARKMAN, LLP  
16th Floor World Trade Center  
121 S.W. Salmon Street  
Portland, Oregon 97204 U.S.A.  
503-226-7391  
(FAX 503-228-9446)

**REQUEST FOR CORRECTED FILING RECEIPT**  
**(TOTAL PAGES TRANSMITTED: 4)**

TO: OFFICE OF INITIAL PATENT EXAMINATION'S  
CUSTOMER SERVICE CENTER

FAX NO.: 703-308-7751

RE: APPLICATION NO: 09/806,440

ART UNIT: 2642

INVENTORS: Miele et al.

ATTY REF.: 4239-58051

FILED: March 30, 2001


TITLE: APOPTOSIS INDUCING AGENTS AND METHODS

Assistant Commissioner For Patents  
Washington, D.C. 20231

An error appears on the official Filing Receipt issued for the above-identified patent application. In particular, two U.S. provisional applications are omitted from the priority data listed on the official Filing Receipt. Attached hereto is a copy of the official Filing Receipt with the requested correction shown thereon. Also attached is a copy of the cover page of the published PCT application, showing the priority claim.

Please correct the identified error and issue a corrected official Filing Receipt.

I hereby certify that this paper and the associated documents are being facsimile transmitted to the Patent & Trademark Office on the date shown below.

  
Sheree Lynn Rybak, Ph.D.  
Registration No. 47,913

April 25, 2002  
Date

cc: Docketing



## UNITED STATES PATENT AND TRADEMARK OFFICE


RECEIVED  
MAY 14 2002  
TECH CENTER 1600/2900  
COMMISSIONER FOR PATENTS  
TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/806,440	03/30/2001	1646	2642	4239-58051	14	79	12

CONFIRMATION NO. 1318

24197  
KLARQUIST SPARKMAN, LLP  
121 SW SALMON STREET  
SUITE 1600  
PORTLAND, OR 97204

## FILING RECEIPT



\*OC000000007799825\*

Date Mailed: 04/05/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Lucio Miele, Morningside, IL;  
Leslie S. Shields, Encinitas, CA;  
Chana Fuchs, Chevy Chase, MD;

## Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/US99/23162 10/01/1999

WHICH CLAIMS BENEFIT OF 60/102,816 10/02/98, AND  
60/124,119 03/12/99

Foreign Applications

Projected Publication Date: Not Applicable, filed prior to November 29, 2000

Non-Publication Request: No

Early Publication Request: No

## Title

Methods and compositions for inducing differentiation and apoptosis in cells tha overexpress the notch protein

## Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER**  
**Title 35, United States Code, Section 184**  
**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

- This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

WO 00/20576

(51) International Patent Classification<sup>7</sup>:

C12N 15/11, A61K 39/395, 31/16, C07K  
16/28, C12N 5/20, G01N 33/574, 33/577,  
A61K 31/475, 31/337, A61P 35/00 //  
C12N 5/06, 5/08, (A61K 39/395, 31:16)  
(A61K 39/395, 31:475) (A61K 39/395,  
31:337)

A2

(11) International Publication Number:

(43) International Publication Date: 13 April 2000 (13.04.00)

(21) International Application Number:

PCT/US99/23162

(22) International Filing Date:

1 October 1999 (01.10.99)

(30) Priority Data:

60/102,816  
60/124,119

2 October 1998 (02.10.98)

12 March 1999 (12.03.99)

US

US

(71) Applicant (for all designated States except US): THE GOV-  
ERNMENT OF THE UNITED STATES OF AMERICA, as  
represented by THE SECRETARY, DEPT. OF HEALTH  
AND HUMAN SERVICES, THE NATIONAL INSTI-  
TUTES OF HEALTH [US/US]; Office of Technology  
Transfer, Suite #325, 6011 Executive Boulevard, Rockville,  
MD 20852 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MIELE, Lucio [IT/US];  
2N771 Morningside Avenue, West Chicago, IL 60185 (US).  
SHIELDS, Leslie, S. [CA/US]; 8507 Capricorn Way #80,  
San Diego, CA 92126 (US). FUCHS, Chana [US/US]; 4450  
S. Park Avenue #1106, Chevy Chase, MD 20815 (US).

(74) Agent: NOONAN, William, D., M., D.; Klarquist, Sparkman,  
Campbell, Leigh & Whinston, LLP, One World Trade  
Center, Suite 1600, 121 S.W. Salmon Street, Portland, OR  
97204 (US).

(11) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG,  
BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE,  
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,  
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,  
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,  
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,  
UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS,  
MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,  
GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished  
upon receipt of that report.

(54) Title: APOPTOSIS INDUCING AGENTS AND METHODS

(57) Abstract

Methods and compositions are disclosed for inducing differentiation and apoptosis in cells that overexpress Notch proteins. A cell fate determining function of Notch is specifically disrupted at a time when the cell is undergoing differentiation, which causes the cell to undergo apoptosis. The invention includes therapies for tumors that overexpress a Notch protein (such as Notch-1) by inducing differentiation of the cells in the tumor with a differentiation inducing agent, such as HMBA, in combination with an agent that disrupts the function of the Notch protein. At a time during which differentiation has been promoted, and the cell is susceptible to interference with the anti-apoptosis effect of Notch, the function of the Notch protein is disrupted. Disruption of Notch function can be achieved, for example, by a differentiation inducing agent such as HMBA, combined with antibodies that specifically bind to Notch and inactivate it, for example a monoclonal antibody that recognizes Notch-1 EGF-like repeats 11 and 12, such as monoclonal antibodies A6, C11 or F3. Disruption of Notch function can also be achieved by the expression of antisense oligonucleotides that specifically interfere with expression of the Notch protein on the cell, alone or in combination with antineoplastic agents.